RxDoctor Payments Data

Matthew Wilson, MD

Cardiovascular Disease · Atlanta, GANPI 1003093600

Payments from drug & device makers

$12,113in general payments, 2019–2025

Across 637 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$1K
  • Boehringer Ingelheim$1K
  • Novartis$900
  • Amarin Pharma, Inc.$840
  • Johnson & Johnson$834
  • plus $6K from 37 others

What the payments were for

  • Speaking & faculty fees$200%
  • Food & beverage$12,075100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,113 in reported general payments places this provider in the 80th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$477,381
Medicare patients
949
Services billed
4,697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban838$926,359
EntrestoSacubitril/Valsartan259$277,209
XareltoRivaroxaban250$276,879
Repatha SureclickEvolocumab240$249,165
JardianceEmpagliflozin203$222,116
FarxigaDapagliflozin Propanediol103$107,857
OzempicSemaglutide58$74,416
MultaqDronedarone Hcl38$61,112
NexlizetBempedoic Acid/Ezetimibe39$35,669
VascepaIcosapent Ethyl44$31,146
Praluent PenAlirocumab26$25,331
VerquvoVericiguat13$23,097
Repatha PushtronexEvolocumab26$22,000
RybelsusSemaglutide16$18,809
LivaloPitavastatin Calcium21$13,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$433$926,359838 claims
NovartisEntresto$900$277,209259 claims
Johnson & JohnsonXarelto$834$276,879250 claims
Boehringer IngelheimJardiance$1,137$222,116203 claims
AstraZenecaFarxiga, Brilinta$1,271$119,206123 claims
Novo NordiskOzempic, Rybelsus$428$93,22574 claims
Sanofi-aventis U.S. LLCMultaq$716$61,11238 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$408$47,99459 claims
MerckVerquvo$730$23,09713 claims
Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor$80$22,27152 claims
Kowa Pharmaceuticals America, Inc.Livalo$322$13,09921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →